Home Biosimilar Antibodies Protein Tyrosine Kinase c-Met Emibetuzumab (Anti-HGFR / c-Met) For research use only.
Not for use in humans.

Emibetuzumab (Anti-HGFR / c-Met)

Synonyms: LY2875358

Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.

Emibetuzumab (Anti-HGFR / c-Met)

Purity & Quality Control

≥99

Choose Selective c-Met Inhibitors

Biological Activity

Description Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.

Product Details

CAS No. 1365287-97-3
Molecular Weight 144.56
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Emibetuzumab (Anti-HGFR / c-Met) | Emibetuzumab (Anti-HGFR / c-Met) supplier | purchase Emibetuzumab (Anti-HGFR / c-Met) | Emibetuzumab (Anti-HGFR / c-Met) cost | Emibetuzumab (Anti-HGFR / c-Met) manufacturer | order Emibetuzumab (Anti-HGFR / c-Met) | Emibetuzumab (Anti-HGFR / c-Met) distributor